Posted by Michael Wonder on 13 Sep 2022
Anthos Therapeutics announces that abelacimab has received FDA fast track designation for the prevention of stroke and systemic embolism in patients with atrial fibrillation
8 September 2022 - This is the second fast track designation issued by the FDA for abelacimab.
Anthos Therapeutics today announced that the US FDA has granted fast track designation for the investigation of abelacimab for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
